Denali Therapeutics Inc. (NasdaqGS:DNLI) announced that it has entered into common stock purchase agreement with new investor Takeda Pharmaceutical Company Limited (TSE:4502) for the private placement of 4,214,559 shares at a price of $26.10 for the gross proceeds of $110,000,000 on January 3, 2018. The transaction is expected to close within ten business day. The securities issued are restricted for transfer including a restriction on acquiring more than 10% for a specified period of time following the closing of the sale of the shares.